Pulmonx Co. (NASDAQ:LUNG) Holdings Boosted by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its position in shares of Pulmonx Co. (NASDAQ:LUNG) by 5.2% during the 3rd quarter, HoldingsChannel reports. The firm owned 313,169 shares of the company’s stock after buying an additional 15,543 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Pulmonx were worth $2,596,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in LUNG. nVerses Capital LLC purchased a new position in shares of Pulmonx during the 3rd quarter valued at $26,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Pulmonx during the 2nd quarter valued at $37,000. Hsbc Holdings PLC purchased a new position in shares of Pulmonx during the 2nd quarter valued at $93,000. Mackenzie Financial Corp purchased a new position in shares of Pulmonx during the 2nd quarter valued at $102,000. Finally, SG Americas Securities LLC purchased a new position in shares of Pulmonx during the 3rd quarter valued at $102,000. 91.04% of the stock is currently owned by hedge funds and other institutional investors.

Pulmonx Price Performance

Shares of Pulmonx stock opened at $6.10 on Monday. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $240.88 million, a price-to-earnings ratio of -4.15 and a beta of 0.69. Pulmonx Co. has a 1-year low of $5.46 and a 1-year high of $14.84. The firm’s 50-day moving average price is $6.56 and its two-hundred day moving average price is $6.88.

Pulmonx (NASDAQ:LUNG) last issued its quarterly earnings data on Wednesday, October 30th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.07. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 53.88%. The firm had revenue of $20.39 million for the quarter, compared to analysts’ expectations of $20.39 million. During the same period in the prior year, the firm earned ($0.39) earnings per share. On average, equities analysts predict that Pulmonx Co. will post -1.53 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on LUNG shares. Citigroup restated a “neutral” rating and set a $7.50 price target (down from $17.00) on shares of Pulmonx in a report on Wednesday, December 11th. Stifel Nicolaus decreased their price objective on shares of Pulmonx from $17.00 to $16.00 and set a “buy” rating for the company in a report on Thursday, October 31st. Finally, Wells Fargo & Company decreased their price objective on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a report on Wednesday, December 11th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Pulmonx currently has an average rating of “Moderate Buy” and an average price target of $12.75.

Insider Activity

In related news, Director Glendon E. French III sold 20,000 shares of the stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $6.63, for a total value of $132,600.00. Following the transaction, the director now directly owns 1,071,974 shares in the company, valued at $7,107,187.62. This represents a 1.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Geoffrey Beran Rose sold 4,376 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $6.18, for a total transaction of $27,043.68. Following the completion of the transaction, the insider now owns 291,057 shares in the company, valued at $1,798,732.26. This represents a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 49,873 shares of company stock valued at $324,070 over the last three months. 5.70% of the stock is owned by insiders.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.